Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify predictive and prognostic variables for overall survival (OS) in chemotherapy-naïve men with mCRPC treated with enzalutamide. Patients and methods: Patients from the PREVAIL trial database (enzalutamide versus placebo) were randomly split 2 : 1 into training (n = 1159) and testing (n = 550) sets. Using the training set, 23 predefined variables were analyzed and a multivariable model predicting OS was developed and validated in an independent testing set. Results: Patient characteristics and outcomes were well balanced between training and testing sets; median OS was 32.7 months in each. The final validated multivariable model included 11 independent prognostic variables. Median OS for low-, intermediate-, and high-risk groups (testing set) defined by prognostic risk tertiles were not yet reached (NYR) (95% CI NYR-NYR), 34.2 months (31.5-NYR), and 21.1 months (17.5-25.0), respectively. Hazard ratios (95% CI) for OS in the low- and intermediate-risk groups versus high-risk group were 0.20 (0.14-0.29) and 0.40 (0.30-0.53), respectively. Secondary outcomes of response and progression differed widely in model-defined risk groups. Enzalutamide improved outcomes in all prognostic risk groups. Conclusions: Our validated prognostic model incorporates variables routinely collected in chemotherapy-naïve men with mCRPC treated with enzalutamide, identifying subsets of patients with widely differing survival outcomes that provide useful information for external validation, patient care, and clinical trial design. Trial registration: ClinicalTrials.gov: NCT01212991.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to visceral metastases, multiple clinical factors have demonstrated an association with varying prognoses, including PSA, alkaline phosphatase, hemoglobin, albumin, and lactate dehydrogenase [48–50].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationTempleton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Self-citationAbiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Self-citationAR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
GLOBOCAN 2008 v1.2, Cancer incidence and mortality world-wide : IARC Cancer Base No. 10
Ferlay, J. (2010) · Medical Entomology and Zoology · Cited by 1,633
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Self-citationRyan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citationPrognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
Adaptive Lasso for Cox's proportional hazards model
Zhang, H. H., & Lu, W. (2007) · Biometrika · doi:10.1093/biomet/asm037 · Cited by 644
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationHalabi, S., Lin, C.-Y., Kelly, W. K., Fizazi, K. S., Moul, J. W., Kaplan, E. B., Morris, M. J., & Small, E. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3696 · Cited by 478
Self-citationHalabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7270 · Cited by 461
Self-citationPlasma AR and abiraterone-resistant prostate cancer
Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9511 · Cited by 441
Beer, T. M., Armstrong, A. J., Rathkopf, D., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Evans, C. P., Kim, C.-S., Kimura, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.07.032 · Cited by 424
Self-citationArmstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C. O., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1036 · Cited by 359
Self-citationPond, G. R., Sonpavde, G., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Armstrong, A. J. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.024 · Cited by 193
Self-citationChi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv594 · Cited by 167
Self-citationProstate cancer: ESMO Consensus Conference Guidelines 2012
Horwich, A., Hugosson, J., de Reijke, T. M., Wiegel, T., Fizazi, K. S., Kataja, V. V., Parker, C. C., Bellmunt, J., Berthold, D., Bill‐Axelson, A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds624 · Cited by 163
Self-citationTempleton, A. J., Pezaro, C., Omlin, A., McNamara, M. G., Leibowitz‐Amit, R., Vera‐Badillo, F. E., Attard, G., de Bono, J. S., Tannock, I. F., & Amir, E. (2014) · Cancer · doi:10.1002/cncr.28890 · Cited by 145
Self-citationArmstrong, A. J., Tannock, I. F., de Wit, R., George, D. J., Eisenberger, M. A., & Halabi, S. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.11.007 · Cited by 132
Self-citationArmstrong, A. J., Saad, F., Phung, D., Dmuchowski, C., Shore, N. D., Fizazi, K. S., Hirmand, M., Forer, D., Scher, H. I., & Bono, J. S. D. (2017) · Cancer · doi:10.1002/cncr.30587 · Cited by 43
Self-citationSonpavde, G., Pond, G. R., Berry, W. R., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Armstrong, A. J. (2011) · Cancer · doi:10.1002/cncr.25982 · Cited by 41
Self-citationRyan, C. J., Kheoh, T. S., Li, J., Molina, A., Porre, P. D., Carles, J., Efstathiou, E., Kantoff, P. W., Mulders, P., Saad, F., et al. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.07.014 · Cited by 33
Tibshirani (1997) · doi:10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3
Research works printed but not linked: 1
- Ferlay, 2016, GLOBOCAN 2012 v10 Cancer Incidence and Mortality Worldwide IARC CancerBase No 11
Cited by
Armstrong, A. J., Lin, P., Tombal, B., Saad, F., Higano, C. S., Joshua, A. M., Parli, T., Rosbrook, B., van Os, S., & Beer, T. M. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.061 · Cited by 168
Self-citationAndrogen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
Jacob, A., Raj, R., Allison, D. B., & Myint, Z. W. (2021) · Cancers · doi:10.3390/cancers13215417 · Cited by 158
“These failures can be partly attributed to AR variants (19-21).”
BackgroundFonseca, N. M., Maurice-Dror, C., Herberts, C., Tu, W., Fan, W., Murtha, A. J., Kollmannsberger, C., Kwan, E. M., Parekh, K., Schönlau, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45475-w · Cited by 145
Guan, Y., Xiong, H., Feng, Y., Liao, G., Tong, T., & Pang, J. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0209-3 · Cited by 90
Gebrael, G., Sahu, K. K., Chigarira, B., Tripathi, N., Mathew Thomas, V., Sayegh, N., Maughan, B. L., Agarwal, N., Swami, U., & Li, H. (2023) · Cancers · doi:10.3390/cancers15143717 · Cited by 85
“For instance, deep learning algorithms have been employed to predict overall survival in patients with metastatic castration-resistant prostate cancer [10].”
Background
Metadata
- Authors
- Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., Krivoshik, A., & Beer, T. M.
- Affiliations
- Duke University (US)
- Pfizer (United States) (US)
- University of Washington (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- University of Alabama at Birmingham (US)
- Cliniques Universitaires Saint-Luc (BE)
- University of Basel (CH)
- Université Paris-Sud (FR)
- Astellas Pharma (Netherlands) (NL)
- Astellas Pharma (United States) (US)
- Oregon Health & Science University (US)
- Corresponding author
- Armstrong, A.J.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 29
- Issue
- 11
- Pages
- 2200-2207
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC6888025
- OpenAlex
- W2892249349
- Cited by
- 71
- References
- 31
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 16 · 2020: 7 · 2019: 6 · 2018: 2
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Funders
- Astellas Pharma, Inc
- Duke Cancer Center's P30 (CA014236)
- US Department of Defense Prostate Cancer Clinical Trials Consortium
- DOD
- PCCTC (W81XWH-14-2-0179)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- metastatic castration-resistant prostate cancer, enzalutamide, prognostic model, overall survival, chemotherapy-naive patients, PREVAIL trial, risk stratification, androgen receptor antagonists, external validation
- MeSH terms
- Progression-Free Survival, Aged, Androgen Antagonists, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Male, Models, Biological, Nitriles, Phenylthiohydantoin, Prognosis, Biomarkers, Tumor, Proportional Hazards Models, Disease Progression, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.